Press Releases

• First patient dosed in the phase II study of tasquinimod in myelofibrosis in the US
  Mar 10, 2025 08:30 (CET)
• First patient enrolled in the HO172 clinical study of tasquinimod in myelofibrosis
  Feb 24, 2025 10:00 (CET)
• Active Biotech Year End Report 2024
  Feb 13, 2025 08:30 (CET) Regulatory
• Number of shares and votes in Active Biotech
  Jan 31, 2025 08:30 (CET) Regulatory
• Active Biotech’s patent for laquinimod in eye disorders granted in the US
  Jan 28, 2025 08:30 (CET)